UCP2 and Parkinson disease: In a mouse model of Parkinson’s disease, we found that transgenic mice overexpressing UCP2 retained significantly more nigral dopamine neurons and had higher striatal dopamine levels after MPTP treatment than wild type (36% cell loss vs. 62% loss in substantia nigra) [66].